Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Joey Luther was arrested last week and charged with wire fraud, smuggling and distributing counterfeit drugs for allegedly ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

MedPharm, a leader in topical and transdermal contract drug development and manufacturing, has appointed Bill Humphries as ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

The adoption of telemedicine and remote monitoring technologies in ophthalmology to accelerate the market growth, says Fact.MR in its new market rese ...

Good morning, and thank you for standing by. Welcome to the AbbVie fourth-quarter 2024 earnings conference call. (Operator Instructions) Today's call is also being recorded. If you have any objections ...

Do you want us to inject Botox into your masseter muscle?” the dentist asked. My brows furrowed, as this is a question I ...

Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...

Non-Surgical Fat Reduction MarketThe global non-surgical fat reduction market is on the verge of a major transformation, with projections indicating a remarkable surge in market value from USD 1,700.5 ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.